94 related articles for article (PubMed ID: 24258993)
1. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract][Full Text] [Related]
2. A growing family: adding mutated Erbb4 as a novel cancer target.
Rudloff U; Samuels Y
Cell Cycle; 2010 Apr; 9(8):1487-503. PubMed ID: 20404484
[TBL] [Abstract][Full Text] [Related]
3. Exome sequencing identifies GRIN2A as frequently mutated in melanoma.
Wei X; Walia V; Lin JC; Teer JK; Prickett TD; Gartner J; Davis S; ; Stemke-Hale K; Davies MA; Gershenwald JE; Robinson W; Robinson S; Rosenberg SA; Samuels Y
Nat Genet; 2011 May; 43(5):442-6. PubMed ID: 21499247
[TBL] [Abstract][Full Text] [Related]
4. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
Zhan Y; Guo J; Yang W; Goncalves C; Rzymski T; Dreas A; Żyłkiewicz E; Mikulski M; Brzózka K; Golas A; Kong Y; Ma M; Huang F; Huor B; Guo Q; da Silva SD; Torres J; Cai Y; Topisirovic I; Su J; Bijian K; Alaoui-Jamali MA; Huang S; Journe F; Ghanem GE; Miller WH; Del Rincón SV
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618965
[No Abstract] [Full Text] [Related]
5. Activating ERBB4 mutations in non-small cell lung cancer.
Kurppa KJ; Denessiouk K; Johnson MS; Elenius K
Oncogene; 2016 Mar; 35(10):1283-91. PubMed ID: 26050618
[TBL] [Abstract][Full Text] [Related]
6. Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.
Jeck WR; Parker J; Carson CC; Shields JM; Sambade MJ; Peters EC; Burd CE; Thomas NE; Chiang DY; Liu W; Eberhard DA; Ollila D; Grilley-Olson J; Moschos S; Neil Hayes D; Sharpless NE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):653-63. PubMed ID: 24628946
[TBL] [Abstract][Full Text] [Related]
7. The genetic basis of new treatment modalities in melanoma.
Kunz M
Curr Drug Targets; 2015; 16(3):233-48. PubMed ID: 25654738
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.
Xia J; Jia P; Hutchinson KE; Dahlman KB; Johnson D; Sosman J; Pao W; Zhao Z
Mol Cancer Ther; 2014 Jul; 13(7):1918-28. PubMed ID: 24755198
[TBL] [Abstract][Full Text] [Related]
9. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP
Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886
[TBL] [Abstract][Full Text] [Related]
10. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
André F; Hurvitz S; Fasolo A; Tseng LM; Jerusalem G; Wilks S; O'Regan R; Isaacs C; Toi M; Burris H; He W; Robinson D; Riester M; Taran T; Chen D; Slamon D
J Clin Oncol; 2016 Jun; 34(18):2115-24. PubMed ID: 27091708
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.
Wali VB; Gilmore-Hebert M; Mamillapalli R; Haskins JW; Kurppa KJ; Elenius K; Booth CJ; Stern DF
Breast Cancer Res; 2014 Dec; 16(6):501. PubMed ID: 25516216
[TBL] [Abstract][Full Text] [Related]
12. Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.
Iurlo A; Gianelli U; Beghini A; Spinelli O; Orofino N; Lazzaroni F; Cambiaghi S; Intermesoli T; Rambaldi A; Cortelezzi A
Oncotarget; 2014 Jul; 5(13):4665-70. PubMed ID: 25015329
[TBL] [Abstract][Full Text] [Related]
13. High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.
Davies S; Holmes A; Lomo L; Steinkamp MP; Kang H; Muller CY; Wilson BS
Int J Gynecol Pathol; 2014 Jul; 33(4):402-10. PubMed ID: 24901400
[TBL] [Abstract][Full Text] [Related]
14. FBXW7 mutations in melanoma and a new therapeutic paradigm.
Aydin IT; Melamed RD; Adams SJ; Castillo-Martin M; Demir A; Bryk D; Brunner G; Cordon-Cardo C; Osman I; Rabadan R; Celebi JT
J Natl Cancer Inst; 2014 Jun; 106(6):dju107. PubMed ID: 24838835
[TBL] [Abstract][Full Text] [Related]
15. Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.
Mirkina I; Hadzijusufovic E; Krepler C; Mikula M; Mechtcheriakova D; Strommer S; Stella A; Jensen-Jarolim E; Höller C; Wacheck V; Pehamberger H; Valent P
PLoS One; 2014; 9(1):e84417. PubMed ID: 24489649
[TBL] [Abstract][Full Text] [Related]
16. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
Janku F; Hong DS; Fu S; Piha-Paul SA; Naing A; Falchook GS; Tsimberidou AM; Stepanek VM; Moulder SL; Lee JJ; Luthra R; Zinner RG; Broaddus RR; Wheler JJ; Kurzrock R
Cell Rep; 2014 Jan; 6(2):377-87. PubMed ID: 24440717
[TBL] [Abstract][Full Text] [Related]
17. HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma.
Nielsen TO; Poulsen SS; Journe F; Ghanem G; Sorensen BS
Melanoma Res; 2014 Feb; 24(1):88-91. PubMed ID: 24366194
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype.
Telesco SE; Vadigepalli R; Radhakrishnan R
Biotechnol J; 2013 Dec; 8(12):1452-64. PubMed ID: 24318637
[TBL] [Abstract][Full Text] [Related]
19. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]